• DOI:10.1016/j.ejphar.2009.11.018
Corpus ID: 24935860

The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.

@article{Bumer2010ThePL,
  title={The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.},
  author={W. B{\"a}umer and P. Wlaź and G. Jennings and C. Rundfeldt},
  journal={European journal of pharmacology},
  year={2010},
  volume={628 1-3},
  pages={
          226-32
        }
}

• W. Bäumer, P. Wlaź, +1 author C. Rundfeldt
• Published 2010
• Medicine
• European journal of pharmacology

Miltefosine is currently marketed for treatment of skin metastasis of breast cancer and leishmaniasis. The mechanism of action is not fully understood, however, miltefosine is considered to be a prototype lipid raft modulator. The compound was shown to inhibit anti-IgE induced histamine release from human skin mast cells. After topical treatment it reduced skin reaction in allergic human volunteers undergoing a skin prick test. The aim of this study was to test whether miltefosine could also… Expand

View on PubMed

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed